

# Marika Rudler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1990782/publications.pdf>

Version: 2024-02-01

55  
papers

1,456  
citations

430442

18  
h-index

329751

37  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1529  
citing authors

#	ARTICLE	IF	CITATIONS
1	ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101784.	0.7	2
2	TIPS for patients with early HCC: A bridge to liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101790.	0.7	6
3	Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "œmenage Å trois". Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101785.	0.7	7
4	A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101801.	0.7	8
5	Metabolomics in the understanding and management of hepatic encephalopathy. Analytical Biochemistry, 2022, 636, 114477.	1.1	4
6	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. , 2022, 1, 393-402.		3
7	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	0.6	97
8	Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!. Journal of Hepatology, 2021, 74, 997-999.	1.8	4
9	Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. United European Gastroenterology Journal, 2021, 9, 203-208.	1.6	17
10	Liver damage associated with Covid-19: A direct causality is difficult to establish. Journal of Liver Transplantation, 2021, 2, 100011.	0.2	0
11	Diagnosis and Management of Hepatic Encephalopathy. Clinics in Liver Disease, 2021, 25, 393-417.	1.0	31
12	Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses!. Liver International, 2021, 41, 1734-1743.	1.9	31
13	Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. Hepatology, 2021, 74, 2085-2101.	3.6	25
14	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	1.8	28
15	Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. Digestive and Liver Disease, 2021, , .	0.4	2
16	TIPS and liver transplantation should always be discussed together. Journal of Hepatology, 2021, 75, 1000-1001.	1.8	5
17	Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101593.	0.7	10
18	Colonic tuberculosis as a cause of massive intestinal bleeding. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101365.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Spécificités de l'hémorragie digestive liée à l'hypertension portale. La Presse Médicale Formation, 2021, 2, 474-474.	0.1	0
20	Optimal management of ascites. Liver International, 2020, 40, 128-135.	1.9	20
21	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	1.8	112
22	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	1.1	10
23	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
24	Pre-emptive TIPS in high-risk patients with cirrhosis and variceal bleeding: is it finally time for a conclusion?. The Lancet Gastroenterology and Hepatology, 2019, 4, 572-573.	3.7	4
25	Management of Complications of Portal Hypertension. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-2.	0.8	6
26	Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?. Journal of Hepatology, 2019, 71, 1055-1057.	1.8	12
27	Unsolved Questions in Salvage TIPSS: Practical Modalities for Placement, Alternative Therapeutics, and Long-Term Outcomes. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-5.	0.8	2
28	Neurocognitive impairment is associated with erectile dysfunction in cirrhotic patients. Digestive and Liver Disease, 2019, 51, 850-855.	0.4	7
29	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 308-320.	1.9	15
30	Proton Pump Inhibitors and Chronic Kidney Disease: Is It Related to the Accumulation of Toxic Breakdown Products Spontaneously Formed in the Enteric-Protected Tablets?. Gastroenterology, 2018, 154, 1204-1205.	0.6	2
31	Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundamental and Clinical Pharmacology, 2018, 32, 209-215.	1.0	17
32	Why and when to measure ammonemia in cirrhosis?. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 505-511.	0.7	17
33	Peak hyperammonemia and atypical acute liver failure: The eruption of an urea cycle disorder during hyperemesis gravidarum. Journal of Hepatology, 2018, 68, 185-192.	1.8	18
34	Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: A large multicentre audit with real-life results. Journal of Hepatology, 2018, 68, 73-81.	1.8	92
35	Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding. Liver International, 2018, 38, 469-476.	1.9	24
36	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	0.6	113

#	ARTICLE	IF	CITATIONS
37	Editorial: predicting hepatic encephalopathy after TIPSS is multimodal cerebral MRI the answer? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1020-1021.	1.9	0
38	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	1.9	28
39	Combined diffusion tensor imaging and magnetic resonance spectroscopy to predict neurological outcome before transjugular intrahepatic portosystemic shunt. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 863-874.	1.9	8
40	Status epilepticus in patients with cirrhosis: How to avoid misdiagnosis in patients with hepatic encephalopathy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 45, 192-197.	0.9	16
41	An unusual cause of massive hematemesis after treatment with terlipressin. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 615-616.	0.7	1
42	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	1.1	13
43	Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2016, 65, 1120-1130.	1.8	109
44	815 Transjugular Intra Hepatic Porto Systemic Shunt (TIPS) Placement Induces Modifications of Cerebral Multimodal MRI in Cirrhotic Patients, Even in the Absence of Development of Hepatic Encephalopathy (HE). <i>Gastroenterology</i> , 2016, 150, S1051.	0.6	1
45	Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, e1-e9.	0.8	70
46	Hepatitis E infection in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1367-1371.	0.8	2
47	Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. <i>Hepatology</i> , 2015, 61, 1024-1032.	3.6	23
48	Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. <i>Journal of Hepatology</i> , 2015, 62, 816-821.	1.8	28
49	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest <sup>®</sup> ) and transient elastography (FibroScan <sup>®</sup> ). <i>Journal of Hepatology</i> , 2014, 60, 706-714.	1.8	101
50	Transfusion strategy in gastrointestinal bleeding: Less is best?. <i>Journal of Hepatology</i> , 2014, 60, 453-454.	1.8	1
51	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest <sup>®</sup> ) and elastography (FibroScan <sup>®</sup> ). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	1.8	42
52	Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 64-71.	0.7	4
53	Salvage transjugular intrahepatic portosystemic shunt followed by early transplantation in patients with Child C14-15 cirrhosis and refractory variceal bleeding: a strategy improving survival. <i>Transplant International</i> , 2013, 26, E50-E51.	0.8	14
54	Gastric mucormycosis: A rare cause of gastrointestinal bleeding in cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e32-e33.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. <i>Liver International</i> , 2006, 26, 271-278.	1.9	95